Treating psoriasis in the elderly: biologics and small molecules
M Megna, L Potestio, G Fabbrocini… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Psoriasis prevalence in the elderly is growing. It is estimated that 15% of elderly
psoriasis patients suffer from moderate-to-severe disease, thus requiring systemic …
psoriasis patients suffer from moderate-to-severe disease, thus requiring systemic …
Treating psoriasis in the elderly: biologics and small molecules.
M Megna, L Potestio, G Fabbrocini… - Expert Opinion on …, 2022 - europepmc.org
Psoriasis prevalence in the elderly is growing. It is estimated that 15% of elderly psoriasis
patients suffer from moderate-to-severe disease, thus requiring systemic treatments …
patients suffer from moderate-to-severe disease, thus requiring systemic treatments …
Treating psoriasis in the elderly: biologics and small molecules
M Megna, L Potestio, G Fabbrocini… - EXPERT OPINION ON …, 2022 - iris.unina.it
Introduction: Psoriasis prevalence in the elderly is growing. It is estimated that 15% of elderly
psoriasis patients suffer from moderate-to-severe disease, thus requiring systemic …
psoriasis patients suffer from moderate-to-severe disease, thus requiring systemic …
Treating psoriasis in the elderly: biologics and small molecules
M Megna, L Potestio, G Fabbrocini… - Expert opinion on …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Psoriasis prevalence in the elderly is growing. It is estimated that 15% of elderly
psoriasis patients suffer from moderate-to-severe disease, thus requiring systemic …
psoriasis patients suffer from moderate-to-severe disease, thus requiring systemic …